Tuberculous meningoencephalitis
ICD-10 A17.82 is a billable code used to indicate a diagnosis of tuberculous meningoencephalitis.
Tuberculous meningoencephalitis is a severe form of central nervous system (CNS) tuberculosis that occurs when Mycobacterium tuberculosis infects the meninges and brain tissue. This condition is characterized by inflammation of the meninges, leading to symptoms such as severe headache, fever, altered mental status, and neurological deficits. Diagnosis typically involves a combination of clinical evaluation, imaging studies such as MRI or CT scans, and laboratory tests including cerebrospinal fluid (CSF) analysis, which may reveal elevated white blood cell counts, low glucose levels, and the presence of acid-fast bacilli. Treatment usually requires a prolonged course of antituberculous medications, including isoniazid, rifampin, pyrazinamide, and ethambutol, often for a duration of 12 months or longer. Monitoring for drug resistance is crucial, as multidrug-resistant tuberculosis (MDR-TB) can complicate treatment. Public health implications are significant, as this condition is contagious and requires contact tracing and isolation procedures to prevent transmission. Early diagnosis and appropriate management are essential to improve outcomes and reduce morbidity associated with this life-threatening condition.
Detailed history of exposure, diagnostic tests, and treatment plans.
Patients presenting with neurological symptoms and a history of tuberculosis.
Need for thorough documentation of drug resistance testing and treatment adherence.
Neurological assessments, imaging results, and CSF findings.
Patients with altered mental status and signs of meningitis.
Documentation of neurological deficits and their progression is critical.
Used to obtain CSF for analysis in suspected cases of meningoencephalitis.
Document indication for the procedure and CSF findings.
Neurology and Infectious Disease specialists should ensure thorough documentation of the procedure.
Common symptoms include severe headache, fever, neck stiffness, altered mental status, and neurological deficits such as seizures or confusion.
Diagnosis is made through clinical evaluation, imaging studies, and analysis of cerebrospinal fluid, which may show elevated white blood cells and the presence of Mycobacterium tuberculosis.
Treatment typically involves a combination of antituberculous medications for an extended period, often 12 months or longer, with close monitoring for drug resistance.
